Friday was an epic day for Stock Markets. Red across the board, and many major support levels being taken out. Why? Fear of a new variant. Omicron out of…
Pharmaceuticals
Looking at the charts of the Psychedelics sector, they can best be described as a mixed bag. Just like Cannabis, shroom stocks are taking a hit. This could just…
There are many cases in today’s market of investors allowing their mob mentality to inefficiently price securities in the public auction market. Sir John Templeton, speaking on market volatility…
Filament Health Corp. (FH.NE) announced today that it has entered into a co-development and exclusive licensing agreement with EntheoTech Bioscience Inc. “Our partnership with EntheoTech showcases our commitment to…
Valeo Pharma Inc. (VPH.C) announced today that it has successfully entered into a Product Listing Agreement (PLA) with the Quebec Minister of Health. According to this agreement, the Company…
Long time readers have been aware that, for some time, Equity.Guru has been a supporter of Canntab Therapeutics (PILL.C), but have been frustrated watching the company being slow on…
Even during my university days, I would find myself grasping my chest, wheezing after a short 15-minute walk to campus. In terms of fitness, I would consider myself to…
In this episode, we revisit Valeo Pharma (VPH.C) to get an update on their product portfolio, stock price, and financials. Is VPH.C a good long term investment? Tune In!…
Valeo Pharma (VPH.C) is a specialty pharmaceutical company, engages in the acquisition, in-licensing, and commercialization of pharmaceutical products with a primary focus on neurodegenerative diseases, oncology and supportive care, and…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…